Clal Biotechnology reported ILS5.73M in Cash and Equivalent for its fiscal quarter ending in December of 2023.





Cash And Equivalent Change Date
aTyr Pharma USD 6.15M 11.07M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 7.46M 985K Sep/2025
RedHill Biopharma USD 2.87M 1.75M Jun/2025